Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $5.52 USD
Change Today +0.11 / 2.03%
Volume 376.4K
NEO On Other Exchanges
Symbol
Exchange
NASDAQ CM
As of 8:10 PM 07/1/15 All times are local (Market data is delayed by at least 15 minutes).

neogenomics inc (NEO) Snapshot

Open
$5.45
Previous Close
$5.41
Day High
$5.55
Day Low
$5.37
52 Week High
09/10/14 - $6.10
52 Week Low
01/22/15 - $3.33
Market Cap
333.2M
Average Volume 10 Days
1.0M
EPS TTM
$0.02
Shares Outstanding
60.4M
EX-Date
--
P/E TM
261.3x
Dividend
--
Dividend Yield
--
Current Stock Chart for NEOGENOMICS INC (NEO)

Related News

No related news articles were found.

neogenomics inc (NEO) Related Businessweek News

No Related Businessweek News Found

neogenomics inc (NEO) Details

NeoGenomics, Inc., together with its subsidiary, NeoGenomics Laboratories, Inc., operates a network of cancer-focused testing laboratories providing genetic and molecular testing services to hospitals, pathologists, oncologists, urologists, other clinicians and researchers, and other laboratories in the United States. The company performs analyses for hematopoietic cancers, such as leukemia and lymphoma; and solid tumor cancers comprising breast, lung, colon, and bladder cancer. It offers cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; immunohistochemistry testing services to localize proteins in cells of a tissue section; and molecular testing services that focus on the analysis of DNA and RNA, as well as on the structure and function of genes at the molecular level. The company was founded in 2001 and is headquartered in Fort Myers, Florida.

440 Employees
Last Reported Date: 04/30/15
Founded in 2001

neogenomics inc (NEO) Top Compensated Officers

Executive Chairman and Chief Executive Office...
Total Annual Compensation: $735.3K
Chief Financial Officer
Total Annual Compensation: $344.0K
Chief Operating Officer
Total Annual Compensation: $88.8K
Chief Compliance Officer, Executive Vice Pres...
Total Annual Compensation: $177.5K
Chief Medical Officer and Director of Researc...
Total Annual Compensation: $131.0K
Compensation as of Fiscal Year 2014.

neogenomics inc (NEO) Key Developments

Neogenomics Inc.(NasdaqCM:NEO) added to Russell 2000 Index

Neogenomics Inc. will be added to Russell 2000 Index

Neogenomics Inc.(NasdaqCM:NEO) added to Russell 3000 Index

Neogenomics Inc. will be added to the Russell 3000 Index.

Neogenomics Inc. Announces New Directors

Neogenomics Inc. announced that Alison L. Hannah, M.D. and Lynn A. Tetrault were elected to its Board of Directors at the Annual Meeting of Shareholders held on June 12, 2015. Dr. Hannah has over 25 years' experience in the development of investigational cancer chemotherapies. Since 2000, she has served as a consultant to the pharmaceutical industry, working with over 20 companies with a focus on molecularly targeted therapy. Prior to this, she worked as Senior Medical Director at SUGEN on various compounds, including Sutent approved in kidney cancer, and Quintiles, a global Contract Research Organization. Dr. Hannah specializes in clinical development strategy, and has filed over 30 Investigational New Drug applications for new molecular entities and 7 New Drug Applications. She participates in Data Monitoring Committees, Scientific Advisory Boards and Independent Review Committees for clinical trials. Ms. Tetrault worked from 1993 to 2014 with AstraZeneca, PLC most recently as Executive Vice President HR and Corporate Affairs. At Astra Zeneca, Ms. Tetrault was responsible for all human resources strategy, talent management, executive compensation and related activities, internal and external communications, government affairs, corporate reputation and corporate social responsibility for the Company.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NEO:US $5.52 USD +0.11

NEO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Enzo Biochem Inc $2.95 USD -0.08
Foundation Medicine Inc $33.88 USD +0.04
Psychemedics Corp $14.51 USD -0.32
Response Genetics Inc $0.30 USD -0.0262
Rosetta Genomics Ltd $3.37 USD -0.02
View Industry Companies
 

Industry Analysis

NEO

Industry Average

Valuation NEO Industry Range
Price/Earnings 100.0x
Price/Sales 3.5x
Price/Book 5.4x
Price/Cash Flow 1,214.1x
TEV/Sales 3.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NEOGENOMICS INC, please visit www.neogenomics.org. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.